Tumor suppressor GENE P53 and its relatives (2606)

Assoc. prof.dr. sc. Neda Slade, zn. Counsellor
Assoc. prof.dr. sc. Marietta the King, zn. Advisor-permanent choice

Rudjer Boskovic Institute, Department of Molecular Medicine

Understand the basis on tumor suppressor genes and their meaning in oncology with an emphasis on the families of genes p53/p63/p73. To know the possibility of using tumor suppressor genes in the gene treatment of tumors.

Tumor supersor genes and their significance in oncology. The key role of the p53 gene in preventing malignant transformation. Family p53/p63/p73 – structural and functional similarities and differences. p53/p63/p73 as transcription factors. The role in cell cycle control and cellular response to DNA damage. Inactivation of the p53 gene as a unique genetic event in the onset of cancer. Analysis of p53 gene mutations in human tumors. Regulation of genes p53/p63/p73in tumors and apoptosis. Role p63/p73 in development. p63 and p73 develop their own identity. Gene p53 and tumor therapy. Gene treatment of tumor tumors with suppressive genes. Combined treatment with chemotherapeutics and genome p53.

1. Explain the importance of p53 in controlling and regulating the normal functioning of the cell.
2. Explain the complexities of the gene structure of p53 family members and the different roles of isoform proteins.
3. Examine the clinical importance of expression of individual isoforms p53/p63/p73.
4. Propose the possibilities of using the results of research so far in prognostic, diagnosis and tumor therapy.

regular attendance, seminar work

Joruiz SM, Bourdon J-C. p53 Isoforms: Key regulators of the Cell Fate Decision. Cold Spring Harbor Perspect Med, 2016, a026039
Candi E, Agostini M, Melino G, Bernassola F. How the TP53 Family proteins TP63 and TP73 contribute to tumorigenesis: regulators and effectors. Hum Mutat 2014, 35:702-714
Moll U.M., Slade N. (2004) p63 and p73: Roles in Development and Tumor Formation. Mol Cancer Res 2: 371-386.
Zorić, A., Horvat, A., Slade, N. Family of genes p53 – role in the development of the organism and tumorigenesis. Medicine Fluminensis 2010 46: 135-143.
http://p53.iarc.fr
Wang Z., Sun Y. Targeting p53 for Novel Anticancer Therapy. Translational Oncology (2010) 3:1-12.
Lane D.P., Cheok C.F., Lain S., p53-based Cancer Therapy. Cold Spring Harb Perspect Biol 2010;2:a001222.
Slade N, Horvat A. Targeting p73-a potential approach in cancer treatment. Curr Pharm Des 2011, 5:591-602 p.m.

Pflaum J, Schlosser S, Müller M. p53 family and cellular stress responses in cancer. Front Oncol, 2014, 00285
Slade N., Zorić A., Horvat A. The p53/p63/p73 family of proteins – the focus on isoforms and mutants in cancer. Period Biol 2010 112: 425–432.
A. I. Robles, C.C. Harris Clinical Outcomes and Correlates of TP53 Mutations and Cancer. Cold Spring Harb Perspect Biol 2010;2:a001016.
Drygin D., O'Brien S.E., Hannan R. D. D, McArthur G.A., Von Hoff D.D. Targeting the nucleolus for cancer-specific activation of p53. Comrade Disco's Today. 2014 Mar;19(3):259-65.
Li Yi, Li Bo, Li Chun-Jie, Li Long-Jiang. Key points of basic theories and clinical practice in. rAd-p53 (Gendicine™) gene therapy for solid malignant tumors. Expert Opinion on Biological Therapy (2015) 15:3, 437-454.

The success of the course will be evaluated annually by the joint expert committee of the Rudjer Boskovic Institute, the University of Dubrovnik and the University of Osijek, and the leaders will receive information from the participants about the adequacy of the program and performance by the leadership through the survey.